InvestorsHub Logo
Followers 0
Posts 30
Boards Moderated 0
Alias Born 05/21/2014

Re: None

Thursday, 11/26/2015 7:30:38 AM

Thursday, November 26, 2015 7:30:38 AM

Post# of 4160
nto, Ontario / ACCESSWIRE / November 26, 2015 / Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has commenced launch of its next generation therapeutic laser, the TLC-2000 Therapeutic Medical Laser System, in the United States.

The United States market represents over 1.3 million practitioners with the ability to purchase the TLC-2000 Therapeutic Medical Laser System for their clinical practices.

David Smith, Director of Global Sales stated, “The FDA approval of the TLC-2000 represents a watershed moment for the Company to dramatically increase its customer base in the US and significantly increase corporate revenue through the sale of the safest and most effective therapeutic laser system ever designed to the largest consumer market in the world. I look forward to building the high performing team that will ultimately lead to these significant revenues for Theralase in 2016 and beyond.”

Roger Dumoulin-White, President and CEO, Theralase stated that, "Theralase has now gained access to the largest consumer market in the world with a technology that is far superior to competitive products in safety, but more importantly in efficacy. I look forward to welcoming the world to the next generation of therapeutic laser technology. The United States remains the largest medical device market in the world with a market size of approximately $110 billion, expected to reach $133 billion by 2016."